X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel is a prescription medicine which is now available in US for the topical treatment of acne vulgaris in patients 12 years of age and older.
Lead Product(s): Clindamycin Phosphate,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Cabtreo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
Xaciato (clindamycin phosphate) vaginal gel 2% is a USFDA approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xaciato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daré Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
Cabtreo (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel which is indicated for the treatment of Acne Vulgaris in patients twelve years of age and older.
Lead Product(s): Clindamycin Phosphate,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Cabtreo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Under the agreement, Daré has the global rights to Xaciato (clindamycin phosphate vaginal gel), an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xaciato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Organon
Deal Size: $192.8 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement October 16, 2023
Details:
The net proceeds will be used the commercial launch of XACIATO (clindamycin phosphate) vaginal gel, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xaciato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Douglas Pharmaceuticals
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 05, 2023
Details:
Xaciato (clindamycin phosphate vaginal gel) inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome, FDA-approved treatment for females 12 and older with bacterial vaginosis.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xaciato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
Esmolol hydrochloride in sodium chloride injection is indicated for tachycardia. Company launched 8 new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays, and prednisolone sodium phosphate oral solution.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Dermatology Product Name: Clindamycin Phosphate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
Under the agreement, Organon licensed global rights to XACIATO (clindamycin phosphate vaginal gel, 2%), an FDA-approved medication for the treatment of bacterial vaginosis in females 12 years of age and older.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xaciato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Organon
Deal Size: $192.5 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement June 30, 2022
Details:
XACIATO is an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older. XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the treatment of bacterial vaginosis.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Xaciato
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daré Bioscience
Deal Size: $192.5 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement March 31, 2022
Details:
IDP-126 Gel, an investigational drug, efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: randomized phase 2 and phase 3 studies of the first triple-combination drug.
Lead Product(s): Clindamycin Phosphate,Benzoyl Peroxide,Adapalene
Therapeutic Area: Dermatology Product Name: IDP-126
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin®1 Foam, 1%, of Mylan Pharmaceuticals Inc which is indicated for acne vulgaris in patients 12 years and older.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Dermatology Product Name: Clindamycin Phosphate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2021
Details:
Clindamycin phosphate EQ 1% topical gel is the generic version of Clindagel, a registered trademark of Bausch Health for treatment of acne .
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Dermatology Product Name: Clindamycin Phosphate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2021
Details:
Glenmark has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Phosphate Gel USP, 1%, the generic version of Cleocin T®1 Gel, 1%, of Pharmacia & Upjohn.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Dermatology Product Name: Clindamycin Phosphate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2021
Details:
DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% being evaluated as a one-time, vaginally-administered treatment for bacterial vaginosis.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: DARE-BV1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
This transaction helps Daré to advance its portfolio of novel investigational products in women’s health, which include DARE-BV1, Sildenafil Cream, and Ovaprene®.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lincoln Park Capital Fund
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Divestment April 23, 2020
Details:
DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit after a single administration in an investigator-initiated proof of concept study.
Lead Product(s): Clindamycin Phosphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
